| Submitted on: 27-08-2018 |
| Ownership of patent(s) |
2001 Shariat S. and Slawin K.: Methods to determine prognosis after therapy for prostate cancer. U.S. Patent Application Serial Number: Docket#60/266,976. Filed May 31, 2001 |
|
2001 Shariat S., Lerner S. and Slawin K.: Methods to determine prognosis after therapy for bladder cancer. U.S. Patent Application Serial Number: Docket#675.003US1. Filed June 1, 2001 |
|
2002 Shariat S., Slawin K., Kattan M., and Scardino P.: Pre- and posttreatment nomograms for predicting recurrence in patients with clinically localized prostate cancer that includes the blood markers interlukin-6 soluble receptor and transforming growth |
|
2003 Slawin K., Kattan M., Shariat S., Stephenson A., and Scardino P.: Nomogram for predicting outcome of salvage radiotherapy for suspected local recurrence of prostate cancer after radical prostatectomy. U.S. Patent Applcation Serial Number: Docket#. Fi |
|
2005 Shariat S.: \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\ |
|
Patent 1 - Granted 2002-09-06 |
|
Patent 2 - Granted 2003-06-19 |
|
Patent 3 - Granted 2004-08-05 |
|
Patent 4 - Granted 2010-07-20 |
| Company consultant |
Astellas |
|
Olympus |
|
Wolff |
|
ipsen |
|
cepheid |
|
janseen |
|
Astrazeneca Österreich GmbH |
|
Bayer Austria GmbH |
|
Ferring Arzneimittel Ges.m.b.h |
|
Pfizer Corporation Austria GmbH |
|
Pierre Fabre Pharma Austria |
|
Sanochemia Pharmazeutika AG |
|
Merck Sharp & Dohme Ges.m.b.H |
|
Eli Lilly |
|
Ipsen Pharma Gmbh |
| Company speaker honorarium |
Lilly |
|
Astellas |
|
Ipsen |
|
olympus |
|
wolff |
|
Janssen |
|
Astrazeneca Österreich GmbH |
|
Bayer Austria GmbH |
|
Ferring Arzneimittel Ges.m.b.h |
|
Pfizer Corporation Austria GmbH |
|
Pierre Fabre Pharma Austria |
|
Sanochemia Pharmazeutika AG |
|
Astellas, AstraZenica, Bayer, BMS, Cepheid, Ferring, Ipsen, Janssen, Lilly |
| Trial participation |
Alere Inc. trials on NMP22 |
|
roche |
|
MSD |
|
bms |
| Participation in a company sponsered speaker's bureau |
bms |
|
msd |
|
roche |
|
ipsen |
|
olympus |
| Other – please indicate |
bms |
|
janssen |
|
wolff |
|
olympus |
|
astellas |
|
msd |
| Receipt of honoraria or consultation fees |
astellas |
|
olympus, |
|
wolff |
|
ipsen |
|
janssen |
|
roche |
|
Astrazeneca Österreich GmbH |
|
Astrazeneca Österreich GmbH |
|
Bayer Austria GmbH |
|
Ferring Arzneimittel Ges.m.b.h |
|
Pfizer Corporation Austria GmbH |
|
Pierre Fabre Pharma Austria |
|
Sanochemia Pharmazeutika AG |
|
Astellas Pharma Ges M.B.H |
|
Merck Sharp & Dohme Ges.m.b.H |
|
Eli Lilly |
| Receipt of grants/research supports |
astellas |
|
sanofi |
